155 related articles for article (PubMed ID: 37439536)
41. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
42. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
43. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
44. Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition.
Severson EA; Haberberger J; Hemmerich A; Huang RSP; Edgerly C; Schiavone K; Najafian A; Hiemenz M; Lechpammer M; Vergilio JA; Lesser G; Strowd R; Elvin J; Ross JS; Hegde P; Alexander B; Singer S; Ramkissoon S
Oncologist; 2023 Jan; 28(1):e26-e35. PubMed ID: 36342081
[TBL] [Abstract][Full Text] [Related]
45. A clinicopathological study of primary central nervous system lymphomas & their association with Epstein-Barr virus.
Sharma MC; Gupta RK; Kaushal S; Suri V; Sarkar C; Singh M; Kale SS; Sahoo RK; Kumar L; Raina V
Indian J Med Res; 2016 May; 143(5):605-15. PubMed ID: 27488004
[TBL] [Abstract][Full Text] [Related]
46. Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.
Sugita Y; Masuoka J; Kameda K; Takahashi K; Kimura Y; Higaki K; Furuta T; Ohshima K
Brain Tumor Pathol; 2020 Oct; 37(4):127-135. PubMed ID: 32627089
[TBL] [Abstract][Full Text] [Related]
47. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
[TBL] [Abstract][Full Text] [Related]
48. Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma.
Lim DH; Kim WS; Kim SJ; Yoo HY; Ko YH
Anticancer Res; 2015 Jun; 35(6):3333-40. PubMed ID: 26026093
[TBL] [Abstract][Full Text] [Related]
49. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
50. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
[TBL] [Abstract][Full Text] [Related]
52. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
Dobashi A
J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
[TBL] [Abstract][Full Text] [Related]
53. Mutational analysis of primary central nervous system lymphoma.
Bruno A; Boisselier B; Labreche K; Marie Y; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Miquel C; Eimer S; Houillier C; Soussain C; Mokhtari K; Daveau R; Hoang-Xuan K
Oncotarget; 2014 Jul; 5(13):5065-75. PubMed ID: 24970810
[TBL] [Abstract][Full Text] [Related]
54. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
Gonzalez-Aguilar A; Idbaih A; Boisselier B; Habbita N; Rossetto M; Laurenge A; Bruno A; Jouvet A; Polivka M; Adam C; Figarella-Branger D; Miquel C; Vital A; Ghesquières H; Gressin R; Delwail V; Taillandier L; Chinot O; Soubeyran P; Gyan E; Choquet S; Houillier C; Soussain C; Tanguy ML; Marie Y; Mokhtari K; Hoang-Xuan K
Clin Cancer Res; 2012 Oct; 18(19):5203-11. PubMed ID: 22837180
[TBL] [Abstract][Full Text] [Related]
55. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
[TBL] [Abstract][Full Text] [Related]
56. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W
Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184
[TBL] [Abstract][Full Text] [Related]
57. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
[TBL] [Abstract][Full Text] [Related]
58. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell.
Montesinos-Rongen M; Brunn A; Bentink S; Basso K; Lim WK; Klapper W; Schaller C; Reifenberger G; Rubenstein J; Wiestler OD; Spang R; Dalla-Favera R; Siebert R; Deckert M
Leukemia; 2008 Feb; 22(2):400-5. PubMed ID: 17989719
[TBL] [Abstract][Full Text] [Related]
59. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
60. Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies.
Hernández-Verdin I; Morales-Martínez A; Hoang-Xuan K; Alentorn A
Curr Opin Neurol; 2022 Dec; 35(6):779-786. PubMed ID: 36367044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]